Skip to main content

Table 3 Risk of outcomes during EDIC follow-up by indices of intraindividual variability of body-weight during the DCCT

From: Body-weight variability and risk of cardiovascular outcomes in patients with type 1 diabetes: a retrospective observational analysis of data from the DCCT/EDIC population

 

All participants

Conventional treatment

Intensive treatment

 

HR (95% C.I.)

p

HR (95% C.I.)

p

HR (95% C.I.)

p

MACE

 ASV

1.34 (1.06–1.66)

0.01

1.50 (1.07–2.05)

0.02

1.15 (0.79–1.62)

0.45

 SD_bw

1.55 (1.20–1.96)

0.0009

1.79 (1.22–2.55)

0.004

1.40 (0.97–1.98)

0.08

 CVAR

1.50 (1.18–1.88)

0.001

1.65 (1.18–2.26)

0.005

1.40 (0.94–2.03)

0.09

 REL_ASV

1.32 (1.03–1.66)

0.03

1.45 (1.03–1.97)

0.03

1.11 (0.72–1.63)

0.63

 VIM

1.50 (1.17–1.88)

0.002

1.64 (1.17–2.23)

0.005

1.40 (0.94–2.04)

0.10

All-cause death

 ASV

1.25 (1.03–1.50)

0.03

1.50 (1.17–1.89)

0.002

1.05 (0.73–1.46)

0.78

 SD_bw

1.42 (1.14–1.76)

0.003

1.69 (1.27–2.18)

0.0005

1.18 (0.82–1.66)

0.37

 CVAR

1.39 (1.11–1.70)

0.004

1.59 (1.22–2.02)

0.0009

1.13 (0.78–1.60)

0.50

 REL_ASV

1.32 (1.08–1.60)

0.008

1.59 (1.23– 2.01)

0.0006

1.10 (0.76–1.54)

0.60

 VIM

1.38 (1.11–1.69)

0.005

1.59 (1.22–2.01)

0.001

1.13 (0.78–1.59)

0.51

  1. Hazard Ratios computed by Cox proportional hazards survival regression analyses for 1 SD of the body-weight variability indices expressed as Z-scores. Regression models adjusted for sex, baseline DCCT body-weight, study treatment allocation during the DCCT, baseline EDIC characteristics, including age, sex, duration of diabetes, eGFR, presence of hyperlipidemia and arterial hypertension, tobacco smoking, and for time-dependent covariates expressed as the average value during DCCT + EDIC follow-up until the first outcome occurrence, comprising BMI, systolic blood pressure, circulating levels of HbA1c, LDL-cholesterol and triglycerides, and UAE. See methods for the definitions of the indices of intraindividual variability of body-weight